Craft
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
banner
Xintian Pharmaceutical financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.

Stock Price

¥11.5

2024-10-29

Market Capitalization

¥2.7 B

2024-10-29

Revenue

¥734.6 M

FY, 2025

CreditSafe Score

?
Score changed on Jun 09, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn more

Financial Statements

CNYFY, 2018FY, 2019FY, 2020FY, 2021FY, 2022FY, 2023FY, 2024FY, 2025
Revenue680.5M760.7M738.7M954.9M1.1B940.2M842.0M734.6M
Cost of goods sold145.7M162.6M165.3M201.2M247.3M218.8M227.7M213.1M
Gross profit535.4M598.8M574.1M754.8M827.2M722.2M615.0M522.5M
Gross profit margin, %76.8%73.0%71.1%
Operating expense total453.3M496.1M469.0M604.9M669.9M606.9M521.9M463.2M
Depreciation and amortization13.4M15.9M18.7M21.6M25.4M20.2M32.3M36.1M
EBITDA82.1M102.6M105.1M149.9M157.3M115.3M93.1M59.2M
EBITDA margin, %12.3%11.1%8.1%
EBIT75.7M87.1M89.6M133.5M133.2M105.1M78.9M27.4M
EBIT margin, %11.2%9.4%3.7%
Interest income616.0K877.0K1.4M1.4M731.0K924.0K674.0K416.0K
Interest expense3.0M6.6M5.5M16.6M10.7M11.8M17.6M17.8M
Pre tax profit81.4M83.0M83.9M116.6M121.6M92.4M60.8M9.8M
Income tax expense11.0M12.2M9.8M16.0M5.5M11.5M8.4M658.0K
Net Income70.4M70.9M74.1M100.6M116.1M80.9M52.3M9.1M

Footer menu